Contact
Contact
Press, research collaboration, programme updates, and financing enquiries each have a clear route below. Financing questions are enquiries only — this website cannot accept investment. For company identity, see About.
Press and general enquiries. Please do not send personal health information, clinical records, or patient-identifiable data by email. This is not a diagnosis service, crisis line, or trial enrolment portal.
Programme updates
Dated notes are on the Updates hub. Email registration is coming soon (news only — not an investment waitlist). Until then, use the subject line below to be notified when the list opens.
Email · Programme updatesResearch collaboration
Scientific or partnership enquiries: please state your institution and the nature of the enquiry. This is not a diagnosis service, crisis line, or trial enrolment portal.
Email · Research collaborationPress
For journalists and media. Put “Press” in the subject. We aim to respond carefully rather than instantly.
Email · PressFinancing enquiries
Enquiry only — not an invest, subscribe, or pay path. Emailing does not confer eligibility, allocation, liquidity, or any investment right. See the FAQ.
We are evaluating a platform-supported route for eligible investors to help finance the CHR-P research programme, including a permissioned digital record of participation at closing where that proves feasible. If a platform path cannot meet legal, operational or investor-access requirements, a conventional private placement with a legal investor register remains the fallback. These are development objectives, not live offering terms. Neither path is available on this website: production investment, payment and token issuance remain inactive. Community updates and discussion are separate from any regulated investment process.
Email · Financing enquiryPrivacy. Email is processed for enquiry handling only. Please do not send personal health information, clinical records, or patient-identifiable data. Prefer organisational contact details where possible.
Available now
- Programme information, Scenario explorer, and Updates articles
- The four enquiry routes on this page
Being developed Not live
- Platform-supported financing path and permissioned digital unit — under evaluation; not live on this site
- Email registration for programme news — coming soon (see Updates and the Programme updates card above)
- No eligibility, allocation, or liquidity on this website
Follow programme updates
Read the Updates hub now. Online registration for email news is coming soon — until then, use Programme updates on this page or the Updates hub. This is news only — not an investment waitlist or token allocation.